UC WAR. PUT 06/24 NOT/ DE000HD4FHM8 /
06/06/2024 13:46:25 | Chg.- | Bid14:15:27 | Ask06/06/2024 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.0090EUR | - | 0.0090 Bid Size: 35,000 |
- Ask Size: 35,000 |
Novartis AG | 90.00 - | 19/06/2024 | Put |
GlobeNewswire
07:00
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPi...
GlobeNewswire
16/04
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
14/03
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
10/01
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
05/01
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire
02/01
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
19/12/2023
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire
11/12/2023
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire
08/12/2023
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire
06/12/2023
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...
GlobeNewswire
20/11/2023
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
GlobeNewswire
19/10/2023
Fairway Consulting Group Appoints Matthew Perry as Vice President of Executive Search
GlobeNewswire
10/10/2023
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis